AbbVie
ABBV
3,750 hedge funds and large institutions have $227B invested in AbbVie in 2024 Q4 according to their latest regulatory filings, with 442 funds opening new positions, 1,501 increasing their positions, 1,412 reducing their positions, and 131 closing their positions.
237% more first-time investments, than exits
New positions opened: 442 | Existing positions closed: 131
7% more funds holding
Funds holding: 3,504 → 3,750 (+246)
6% more call options, than puts
Call options by funds: $3.18B | Put options by funds: $2.99B
6% more repeat investments, than reductions
Existing positions increased: 1,501 | Existing positions reduced: 1,412
0.62% more ownership
Funds ownership: 71.69% → 72.3% (+0.62%)
9% less capital invested
Capital invested by funds: $250B → $227B (-$22.7B)
19% less funds holding in top 10
Funds holding in top 10: 208 → 168 (-40)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.11B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$821M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$806M |
| 4 |
Charles Schwab
San Francisco,
California
|
+$662M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$620M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$1.52B |
| 2 |
Janus Henderson Group
London,
|
-$1.07B |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$857M |
| 4 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$762M |
| 5 |
Bank of New York Mellon
New York
|
-$625M |
ABBV Hedge Fund Activity: Q4 2024 in Review
3,750 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2024, worth a combined $227B — down 9.1% from $250B a quarter earlier.
Buyers outnumbered sellers: 442 funds opened new ABBV positions and 131 closed out — a net gain of 311 holders — while 1,501 added to existing stakes and 1,412 trimmed.
The largest buyer was BlackRock, adding an estimated $1.11B. The largest seller was Capital International Investors, cutting an estimated $1.52B.
- 3,750 institutional investors held AbbVie (ABBV) as of Q4 2024, up from 3,504 in Q3 2024.
- Funds reported $227B of AbbVie stock for Q4 2024, down 9.1% quarter-over-quarter.
- 442 funds opened new AbbVie positions in Q4 2024 and 131 closed out, a net change of +311 holders.
- The largest AbbVie buyer in Q4 2024 was BlackRock, an estimated $1.11B added.
- The largest AbbVie seller in Q4 2024 was Capital International Investors, an estimated $1.52B sold.
Based on aggregated 13F filings for Q4 2024.